← Back to headlines
AstraZeneca's Camizestrant Faces FDA Setback
An FDA committee has declined to endorse AstraZeneca's experimental breast cancer drug, camizestrant, marking a setback for the pharmaceutical company.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
